Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17746917 | 0.78 | BRPF1 (0.50) | — | |
| SCHEMBL6563314 | 0.75 | MCL1 (0.40) | — | |
| SCHEMBL6562476 | 0.72 | TNF (0.46) | — | |
| SCHEMBL12278113 | 0.72 | GPR55 (0.39) | GOT1P2RX7 | |
| SCHEMBL28947821 | 0.72 | CYP1A2 (0.44) | GOT1P2RX7 | |
| SCHEMBL3382822 | 0.71 | MEN1 (0.44) | — | |
| SCHEMBL2320833 | 0.71 | CTSA (0.47) | — | |
| SCHEMBL5720952 | 0.71 | CTSA (0.47) | — | |
| SCHEMBL2320843 | 0.71 | CTSA (0.47) | — | |
| SCHEMBL3864299 | 0.70 | KMT2A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004536071-A | — | — | 2004-12-02 | — | — | JP | claimed |
| EP-1397136-A1 | HETEROCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-03-17 | — | — | EP | claimed |
| WO-2002096424-A1 | HETEREOCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-12-05 | — | — | WO | claimed |
| EP-1397136-A1 | HETEROCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096424-A1 | HETEREOCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-12-05 | — | — | WO | disclosed |